Geovax Labs (Geovax Labs) Notes Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Notes Receivable?

Geovax Labs's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Geovax Labs Notes Receivable Historical Data

The historical data trend for Geovax Labs's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Notes Receivable Chart

Geovax Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Notes Receivable

Get a 7-Day Free Trial

Geovax Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Geovax Labs Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Geovax Labs Notes Receivable Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

E8L:Germany E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Executives

Mckee Kelly T. Jr.	officer: Chief Medical Officer	233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd	director	C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds	officer: Chief Financial Officer	TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan	director	1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase	director	28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey	officer: VP, Business Development	16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas	director	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr	director	2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally	director
Farshad Guirakhoo	officer: Sr VP, Research & Development	39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi	director	10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson	other: Chair, Scientific Adv Brd	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman	officer: VP, Research & Development	1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas	director	123 JOAN DRIVE, BARRINGTON IL 60010